Syntracts | $5,300,000 | (Oct 24, 2025)
GradBridge | $20,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Alpha-9 Oncology
United States
- Boston, Massachusetts
- 24/10/2024
- Series C
- $175,000,000
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
- Industry Biotechnology Research
- Website https://www.a9oncology.com/
- LinkedIn https://www.linkedin.com/company/a9oncology/
CipherOwl | $15,000,000 | (Oct 24, 2025)
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
Vermeer | $10,000,000 | (Oct 24, 2025)
GammaTime | $14,000,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Apriority Financial, Inc. | $2,300,000 | (Oct 24, 2025)
OneAM | $4,700,000 | (Oct 24, 2025)
🌱 Rightcharge | $2,131,920 | (Oct 24, 2025)
Tensormesh | $4,500,000 | (Oct 24, 2025)